1. Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia;Ozeki;Blood,2004
2. R.M. Stone, S. Mandrekar, B.L. Sanford, S. Geyer, C.D. Bloomfield, K. Dohner, et al., The multi-kinase inhibitor midostaurin (M) prolongs survival compared with placebo (P) in combination with daunorubicin (D)/cytarabine (C) induction (ind), high-dose C consolidation (consol), and As maintenance (maint) therapy in newly diagnosed acute myeloid leukemia (AML) patients (pts) age 18–60 with FLT3 mutations (muts): an international prospective randomized (rand) P-controlled double-blind trial (CALGB 10603/RATIFY [Alliance]), in: Presented at the 57th Annual Meeting of the American Society of Hematology.
3. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia;The Cancer Genome Atlas Research Network;N. Engl. J. Med.,2013
4. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia;Patel;N. Engl. J. Med.,2012
5. A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia;Lancet;Haematologica,2014